Opioid-related ambulance attendances during the first 2 years of the COVID-19 pandemic in Victoria, Australia.

BACKGROUND AND AIMS Public health measures introduced to contain the spread of the SARS-CoV-2 virus likely affected opioid supply and demand, as well as the patterns and contexts of opioid use. We measured opioid-related harms during the first 2 years of COVID-19 restrictions in Victoria, Australia. DESIGN We adopted an interrupted time series analysis design using interventional autoregressive integrated moving average (ARIMA) models. Opioid-related ambulance attendance data between January 2015 and March 2022 were extracted from the National Ambulance Surveillance System. SETTING Victoria, Australia. PARTICIPANTS Patients (≥15 years) attended to by an ambulance for opioid-related harms. MEASUREMENTS Monthly opioid-related ambulance attendances for three drug types: heroin, prescription opioids and opioid agonist therapy (OAT) medications. FINDINGS The monthly rate of heroin-related attendances fell by 26% immediately after the introduction of COVID-19 restrictions. A reduced rate of heroin-related attendances was observed during COVID-19 restrictions, resulting in 2578 averted heroin-related attendances. There was no change in the rate of attendances for extra-medical OAT medications or prescription opioids. CONCLUSIONS Strict COVID-19 restrictions in Victoria, Australia appear to have resulted in a substantial reduction in heroin-related ambulance attendances, perhaps because of border closures and restrictions on movement affecting supply, changing patterns of drug consumption, and efforts to improve access to OAT. Despite policy changes allowing longer OAT prescriptions and an increased number of unsupervised doses, we found no evidence of increased harms related to the extra-medical use of these medications.

[1]  Scott Harrison,et al.  Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review , 2023, International Journal of Drug Policy.

[2]  N. Harnedy,et al.  Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis , 2023, Journal of Substance Use and Addiction Treatment.

[3]  C. Brummett,et al.  Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review , 2022, Regional Anesthesia & Pain Medicine.

[4]  J. Sveticic,et al.  Comparison of the characteristics of patients treated with sublingual vs. long-acting injectable buprenorphine formulations for treatment of opioid use disorder: A retrospective cohort study , 2022, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[5]  R. Kleinman,et al.  Is daily supervised buprenorphine-naloxone dosing necessary? , 2022, BMJ.

[6]  P. Butterworth,et al.  Protecting mental health during periods of financial stress: Evidence from the Australian Coronavirus Supplement income support payment , 2022, Social Science & Medicine.

[7]  T. Gomes,et al.  Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions , 2022, International Journal of Drug Policy.

[8]  L. Brener,et al.  Health worker perceptions of the impact of COVID‐19 on harm reduction services for people who inject drugs , 2022, Health & social care in the community.

[9]  P. Higgs,et al.  Health service utilisation and access for people who inject drugs during COVID‐19 , 2022, Drug and alcohol review.

[10]  T. Gomes,et al.  Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. , 2022, JAMA.

[11]  R. Ghose,et al.  Impact of the COVID-19 Pandemic on Opioid Overdose Deaths: a Spatiotemporal Analysis , 2022, Journal of Urban Health.

[12]  M. Kyrios,et al.  A cross-sectional investigation of the mental health and wellbeing among individuals who have been negatively impacted by the COVID-19 international border closure in Australia , 2022, Globalization and Health.

[13]  N. Lintzeris,et al.  Opioid agonist treatment and patient outcomes during the COVID‐19 pandemic in south east Sydney, Australia , 2021, Drug and alcohol review.

[14]  P. Haber,et al.  Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. , 2021, Drug and alcohol dependence.

[15]  D. Lubman,et al.  Challenges in delivering telemedicine to vulnerable populations: experiences of an addiction medical service during COVID‐19 , 2021, The Medical journal of Australia.

[16]  Alexandra Voce,et al.  Declines in methamphetamine supply and demand in Australia during the COVID-19 pandemic , 2021 .

[17]  Alexandra Voce,et al.  Drug use monitoring in Australia: drug use among police detainees, 2020 , 2021 .

[18]  S. Lenton,et al.  Changes in illicit drug use and markets with the COVID‐19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016–20 , 2021, Addiction.

[19]  T. Dobbins,et al.  Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions , 2021, BMC Medical Research Methodology.

[20]  S. Nielsen,et al.  Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia , 2021, Harm Reduction Journal.

[21]  Justin Jager,et al.  Is substance use changing because of the COVID‐19 pandemic? Conceptual and methodological considerations to delineating the impact of the COVID‐19 pandemic on substance use and disorder , 2021, Addiction.

[22]  N. Lintzeris,et al.  Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges , 2020, Journal of Substance Abuse Treatment.

[23]  Cameron Parsell,et al.  Understanding responses to homelessness during COVID-19: an examination of Australia , 2020, Housing Studies.

[24]  Kathy T. LeSaint,et al.  Opioid Overdose–Related Emergency Department Visits and Accidental Deaths during the COVID-19 Pandemic , 2020, Journal of Urban Health.

[25]  Tamas S. Gal,et al.  Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic. , 2020, JAMA.

[26]  S. Ward,et al.  Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. , 2020, Addiction.

[27]  B. Lloyd,et al.  National Ambulance Surveillance System: A novel method using coded Australian ambulance clinical records to monitor self-harm and mental health-related morbidity , 2020, PloS one.

[28]  Peter J. Rock,et al.  Signal of increased opioid overdose during COVID-19 from emergency medical services data , 2020, Drug and Alcohol Dependence.

[29]  P. Haber,et al.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic , 2020, Harm Reduction Journal.

[30]  P. Dietze,et al.  Illicit drug use and harms in Australia in the context of COVID‐19 and associated restrictions: Anticipated consequences and initial responses , 2020, Drug and alcohol review.

[31]  B. Lloyd,et al.  The National Ambulance Surveillance System: A novel method for monitoring acute alcohol, illicit and pharmaceutical drug related-harms using coded Australian ambulance clinical records , 2020, PloS one.

[32]  Don Weatherburn,et al.  Supply control and harm reduction: lessons from the Australian heroin 'drought'. , 2003, Addiction.